15353-j-veluchamy

6 General discussion and Future Prospects | 151 still very effective platform, to bring CAR-based therapies to broader clinical applications. It may also facilitate effective tumor targeting of NK cells. oNKord ® and iPSC derived NK cells could serve as alternative allogeneic platforms to develop CAR-NK products, beside NK cell lines. In a solid tumor setting, NK cells are challenged by several factors that affect their homing and penetration into the tumor tissues. Moreover, they should achieve and maintain an activated effector state, even in the face of immune suppressive conditions, that are prevalent in patients with cancer. To overcome these bottlenecks in NK therapy of solid tumors, a plethora of creative solutions are being pursued by numerous research labs as well as by biotech companies in clinical or close-to-clinical phase. Strategies to enhance NK cell functions from leading NK cell products are summarized in Figure 2. With all these exciting developments, NK cells are set to make a considerable impact on the future treatment of patients with haematological as well as with solid tumors. Figure 2: A Summary of various strategies to augment NK cell functions.